- Home
- ECF vs ATOS Comparison
ECF vs ATOS Comparison
Compare ECF & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECF
- ATOS
- Stock Information
- Founded
- ECF 1986
- ATOS 2009
- Country
- ECF United States
- ATOS United States
- Employees
- ECF N/A
- ATOS N/A
- Industry
- ECF Finance/Investors Services
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- ECF Finance
- ATOS Health Care
- Exchange
- ECF Nasdaq
- ATOS Nasdaq
- Market Cap
- ECF 136.0M
- ATOS 114.5M
- IPO Year
- ECF N/A
- ATOS 2012
- Fundamental
- Price
- ECF $9.88
- ATOS $0.80
- Analyst Decision
- ECF
- ATOS Strong Buy
- Analyst Count
- ECF 0
- ATOS 3
- Target Price
- ECF N/A
- ATOS $7.00
- AVG Volume (30 Days)
- ECF 57.7K
- ATOS 678.1K
- Earning Date
- ECF 01-01-0001
- ATOS 03-31-2025
- Dividend Yield
- ECF 6.42%
- ATOS N/A
- EPS Growth
- ECF N/A
- ATOS N/A
- EPS
- ECF 0.46
- ATOS N/A
- Revenue
- ECF N/A
- ATOS N/A
- Revenue This Year
- ECF N/A
- ATOS N/A
- Revenue Next Year
- ECF N/A
- ATOS N/A
- P/E Ratio
- ECF $17.61
- ATOS N/A
- Revenue Growth
- ECF N/A
- ATOS N/A
- 52 Week Low
- ECF $7.02
- ATOS $0.72
- 52 Week High
- ECF $8.91
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- ECF 46.69
- ATOS 41.00
- Support Level
- ECF $9.87
- ATOS $0.79
- Resistance Level
- ECF $10.12
- ATOS $0.89
- Average True Range (ATR)
- ECF 0.11
- ATOS 0.05
- MACD
- ECF -0.01
- ATOS 0.01
- Stochastic Oscillator
- ECF 4.00
- ATOS 25.14
About ECF Ellsworth Growth and Income Fund Ltd.
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.